<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordsOutput><serviceExecutionTime>330</serviceExecutionTime><Drug id="101764"><DrugName>BOS-356</DrugName><DrugSynonyms><Name><Value>GSK-3008356</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>3008356</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>DGAT-1 inhibitor (oral, non-alcoholic steatohepatitis), GSK</Value></Name><Name><Value>BOS-356</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="28355">GlaxoSmithKline plc</CompanyOriginator><CompaniesPrimary><Company id="1116437">Boston Pharmaceuticals</Company></CompaniesPrimary><CompaniesSecondary><Company id="28355">GlaxoSmithKline plc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="1116437" type="Company"><TargetEntity id="5047646600" type="organizationId">Boston Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="28355" type="Company"><TargetEntity id="4295895781" type="organizationId">GlaxoSmithKline PLC</TargetEntity></SourceEntity><SourceEntity id="2637" type="ciIndication"><TargetEntity id="K75.81" type="ICD10"></TargetEntity><TargetEntity id="1412" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3" type="ciIndication"><TargetEntity id="L70" type="ICD10"></TargetEntity><TargetEntity id="706.1" type="ICD9"></TargetEntity><TargetEntity id="10000496" type="MEDDRA"></TargetEntity><TargetEntity id="443" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity></SourceEntity><SourceEntity id="38825" type="Action"><TargetEntity id="2607" type="Mechanism">Diacylglycerol Acyltransferase Type 1 (DGAT-1) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="PTGT-07247" type="ciTarget"><TargetEntity id="6432317286943" type="siTarget">Diacylglycerol O-acyltransferase 1</TargetEntity><TargetEntity id="9061" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="C1">Phase 1 Clinical</PhaseHighest><IndicationsPrimary><Indication id="3">Acne</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="2637">Non-alcoholic steatohepatitis</Indication></IndicationsSecondary><ActionsPrimary><Action id="38825">Diacylglycerol O acyltransferase 1 inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="2953">Anti-inflammatory</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology><Technology id="585">Oral formulation</Technology></Technologies><EphmraCodes><Ephmra><Code>D10</Code><Name>ANTI-ACNE PREPARATIONS</Name></Ephmra></EphmraCodes><LastModificationDate>2018-10-05T10:43:52.000Z</LastModificationDate><ChangeDateLast>2018-10-05T00:00:00.000Z</ChangeDateLast><AddedDate>2016-04-25T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1116437" linkType="Company"&gt;Boston Pharmaceuticals&lt;/ulink&gt;, under license from &lt;ulink linkID="28355" linkType="Company"&gt;GlaxoSmithKline&lt;/ulink&gt;, is developing BOS-356 (presumed to be formerly GSK-3008356 (3008356)), a diglyceride acyltransferase (DGAT)-1 inhibitor, for the potential treatment of acne [&lt;ulink linkID="1755052" linkType="Reference"&gt;&lt;/ulink&gt;&lt;ulink linkID="2078661" linkType="Reference"&gt;2078661&lt;/ulink&gt;], [&lt;ulink linkID="2079309" linkType="Reference"&gt;2079309&lt;/ulink&gt;]. In October 2018, the drug was listed as being in phase  I [&lt;ulink linkID="2079309" linkType="Reference"&gt;2079309&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Glaxosmithkline was previously developing the drug for the potential treatment of non-alcoholic steatohepatitis [&lt;ulink linkID="1755052" linkType="Reference"&gt;1755052&lt;/ulink&gt;], [&lt;ulink linkID="1908662" linkType="Reference"&gt;1908662&lt;/ulink&gt;]. In March 2016, a  phase I study   was initiated in Australia in healthy and obese subjects [&lt;ulink linkID="1755052" linkType="Reference"&gt;1755052&lt;/ulink&gt;]. In March 2017, phase I development was ongoing [&lt;ulink linkID="1908662" linkType="Reference"&gt;1908662&lt;/ulink&gt;]. However, in July 2017, the company decided to terminate, partner or divest the program [&lt;ulink linkID="1950392" linkType="Reference"&gt;1950392&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In March 2016, a randomized, placebo-controlled, double-blind phase I study (&lt;ulink linkID="258698" linkType="Protocol"&gt;NCT02742766&lt;/ulink&gt;; 204856) was initiated in Australia in healthy and obese subjects (n = 94). 	The trial was expected to complete in May 2017 [&lt;ulink linkID="1755052" linkType="Reference"&gt;1755052&lt;/ulink&gt;].&lt;br&gt;&lt;/br&gt;&lt;br&gt;&lt;/br&gt;&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1116437">Boston Pharmaceuticals</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="3">Acne</Indication><StatusDate>2018-10-03T00:00:00.000Z</StatusDate><Source id="2078661" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="2637">Non-alcoholic steatohepatitis</Indication><StatusDate>2017-07-26T00:00:00.000Z</StatusDate><Source id="1950392" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="3">Acne</Indication><StatusDate>2018-10-03T00:00:00.000Z</StatusDate><Source id="2078661" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="2637">Non-alcoholic steatohepatitis</Indication><StatusDate>2016-03-31T00:00:00.000Z</StatusDate><Source id="1755052" type="TRIALREG"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-07247"><Name>Diacylglycerol O acyltransferase 1</Name><SwissprotNumbers><Swissprot>O75907</Swissprot><Swissprot>Q8MK44</Swissprot><Swissprot>Q9ERM3</Swissprot><Swissprot>Q9GMF1</Swissprot><Swissprot>Q9Z2A7</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=2078661" linkType="reference" linkID="2078661"&gt;2078661&lt;/ulink&gt;]							</Description></ReasonForUpdate><ReasonForUpdate><Reason>Deal Summary Added/Updated</Reason><Description>Deal summary added/updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1116437">Boston Pharmaceuticals</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="28355">GlaxoSmithKline plc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="250186" title="Boston to develop GlaxoSmithKline's GSK-3352589, GSK-3008356, GSK-3183475 and two undisclosed preclinical programs against various indications  "/></Deals><hasSWOTs>N</hasSWOTs></Drug></drugRecordsOutput>